Samil Pharmaceutical Co., Ltd. (000520) Stock Statistics & Valuation Metrics

Samil Pharmaceutical Co., Ltd. has a market cap or net worth of KRW 159.69B. The enterprise value is KRW 310.98B.

Market Cap

KRW 159.69B

Enterprise Value

KRW 310.98B

Samil Pharmaceutical Co., Ltd. has 21,691,810 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

21,691,810

Owned by Insiders

―

Owned by Institutions

0.62%

Samil Pharmaceutical Co., Ltd.’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -6.80%.

Return on Equity (ROE)

-0.26

Return on Assets (ROA)

-0.09

Return on Invested Capital (ROIC)

-6.80%

Return on Capital Employed (ROCE)

-0.13

Revenue Per Employee

359.60M

Profits Per Employee

-59.13M

Employee Count

585

Asset Turnover

0.57

Inventory Turnover

4.10

The current PE Ratio of Samil Pharmaceutical Co., Ltd. is -4.07. Samil Pharmaceutical Co., Ltd.’s PEG ratio is 0.07.

PE Ratio

-4.07

PS Ratio

0.74

PB Ratio

1.22

Price to FCF

-20.62

Price to Operating Cash Flow

-5866.43

PEG Ratio

0.07

In the last 12 months, Samil Pharmaceutical Co., Ltd. had revenue of 210.37B and earned -34.59B in profits. Earnings per share was -1627.95.

Revenue

210.37B

Gross Profit

67.44B

Operating Income

-23.94B

Pretax Income

-37.16B

Net Income

-34.59B

EBITDA

-10.72B

Earnings Per Share (EPS)

-1627.95

In the last 12 months, operating cash flow was -26.12M and capital expenditures -7.41B, giving a free cash flow of -7.43B billion.

Operating Cash Flow

-26.12M

Free Cash Flow

-7.43B

Free Cash Flow per Share

-347.77

Samil Pharmaceutical Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-4.85%

Earnings Yield

-24.50%

Beta

0.04

52-Week Price Change

-31.58%

50-Day Moving Average

7715.20

200-Day Moving Average

8153.00

Relative Strength Index (RSI)

40.78

Average Volume (3m)

81.34K

Samil Pharmaceutical Co., Ltd. upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).

Last Earnings Date

Aug 14, 2026

Next Earnings Date

Nov 18, 2026

Ex-Dividend Date

―

Samil Pharmaceutical Co., Ltd. as a current ratio of 0.44, with Debt / Equity ratio of 123.08%

Current Ratio

0.44

Quick Ratio

0.25

Debt to Market Cap

0.79

Net Debt to EBITDA

-14.70

Interest Coverage Ratio

-2.73

In the past 12 months, Samil Pharmaceutical Co., Ltd. has paid -2.49B in taxes.

Income Tax

-2.49B

Effective Tax Rate

0.07

Samil Pharmaceutical Co., Ltd. EV to EBITDA ratio is -19.73, with an EV/FCF ratio of -43.48.

EV to Sales

1.56

EV to EBITDA

-19.73

EV to Free Cash Flow

-43.48

EV to Operating Cash Flow

-12372.60

Samil Pharmaceutical Co., Ltd. has KRW 6.11B in cash and marketable securities with KRW 176.05B in debt, giving a net cash position of -KRW 169.93B billion.

Cash & Marketable Securities

KRW 6.11B

Total Debt

KRW 176.05B

Net Cash

-KRW 169.93B

Net Cash Per Share

-KRW 7,833.94

Tangible Book Value Per Share

KRW 5,622.58

Gross margin is 32.13%, with operating margin of -14.53%, and net profit margin of -18.09%.

Gross Margin

32.13%

Operating Margin

-14.53%

Pretax Margin

-19.07%

Net Profit Margin

-18.09%

EBITDA Margin

-7.90%

EBIT Margin

-14.66%

The average price target for Samil Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target

―

Price Target Upside

―

Analyst Consensus

―

Analyst Count

―

Revenue Growth Forecast

-4.54%

EPS Growth Forecast

-88.02%

Smart Score

―

AI Score

47